Pharma News
FDA Approves Balversa for Locally Advanced, Metastatic Urothelial Carcinoma
![](https://meefro.com/wp-content/uploads/2024/01/FDA-Approves-Balversa-for-Locally-Advanced-Metastatic-Urothelial-Carcinoma.png)
Today’s FDA approval amends a previously granted accelerated approval for Balversa (erdafitinib) to treat patients with metastatic urothelial carcinoma whose tumors harbor FGFR3 or FGFR2 alterations following prior platinum-based chemotherapy.
Source link
#FDA #Approves #Balversa #Locally #Advanced #Metastatic #Urothelial #Carcinoma